Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 137

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 137
---
 for our securities following the Business Combination may never develop or, if developed, it may not be sustained. In addition, the price of our securities after the Business Combination can vary due to general economic conditions and forecasts, our general business condition and the release of financial reports. Additionally, if our securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter -dealerautomated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if they were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained. If, following the Business Combination, securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our securities adversely, then the price and trading volume of our securities could decline. The trading market for our Company Shares will be influenced by the research and reports that industry or securities analysts may publish about the us, our business, our market, or our competitors. If no securities or industry analysts commence to cover us, the trading price and volume of our securities would likely be negatively impacted. If any of the analysts who may cover us adversely change their recommendation regarding our securities, or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst who may cover SPAC were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price of trading volume of our securities to decline. We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our ordinary shares. We have identified material weaknesses in our internal control over financial reporting in respect of OmnigenicsAI. Further, the management of APx has identified and reported material weaknesses (see “ — Risks Related to APx — APx has identified material weaknesses in its internal control over financial reporting. If APx is unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, it may not be able to accurately or timely report its financial condition or results of operations,